4D Molecular Therapeutics Inc. - notizie pubblicate 191 - letture 5.409
4D MOLECULAR THERAPEUTICS INC.
Annual Report for Fiscal Year Ending December 31, 2023 (Form 10-K)
10-k united states securities and exchange commission washington, d.c. 20549 form 10-k (mark one) ☒ annual report pursuant to section 13 or 15(d) of the securities exchange act o ...
4D MOLECULAR THERAPEUTICS INC.
Initial Registration Statement for Employee Benefit Plan - Form S-8
S-8 as filed with the securities and exchange commission on february 29, 2024 registration no. 333- united states securities and exchange commission washington, d.c. 20549 form s-8 ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
4DMT Presents Interim Data from 4D-310 INGLAXA Phase 1/2 Clinical Trials for Fabry Disease Cardiomyopathy at WORLDSymposium™ 2024
4d-310 demonstrated clinically meaningful cardiac endpoint improvements through 12-24 months in contractility (echocardiography), peak vo2 (cardiopulmonary exercise testing) and/or ...
4D MOLECULAR THERAPEUTICS INC.
Material Event - Form 8-K
Item 8.01 other events. on february 6, 2024, 4d molecular therapeutics, inc. (the "company") entered into an underwriting agreement (the "underwriting agreement" ...
4D MOLECULAR THERAPEUTICS INC.
Supplemental Prospectus - Form 424B5
424b5 table of contents filed pursuant to rule 424(b)(5) registration no. 333-276872 prospectus supplement (to prospectus dated february 5, 2024) 6,586,015 shares of common stock p ...
4D MOLECULAR THERAPEUTICS INC.
Statement of Changes in Beneficial Ownership - Form 4
Ownership submission form 4 check this box if no longer subject to section 16, form 4 or form 5 obligations may continue. see instruction 1(b). united states securities and exchang ...
4D MOLECULAR THERAPEUTICS INC.
Amendment to Initial Statement of Beneficial Ownership - Form 3/A
Ownership submission form 3/a united states securities and exchange commission washington, d.c. 20549initial statement of beneficial ownership of securities filed pursuant to secti ...
4D MOLECULAR THERAPEUTICS INC.
Free Writing Prospectus - Form FWP
Fwp issuer free writing prospectus filed pursuant to rule 433 dated february 6, 2024 relating to preliminary prospectus supplement dated february 5, 2024 registration statement no. ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
Emeryville, calif., feb. 06, 2024 (globe newswire) -- 4d molecular therapeutics, inc. (nasdaq: fdmt), a leading clinical-stage genetic medicines company focused on unlocking the fu ...
4D MOLECULAR THERAPEUTICS INC.
Supplemental Prospectus - Form 424B5
424b5 table of contents filed pursuant to rule 424(b)(5) registration no. 333-276872 the information contained in this preliminary prospectus supplement is not complete and may be ...
4D MOLECULAR THERAPEUTICS INC.
Automatic Shelf Registration Statement - Form S-3ASR
S-3asr table of contents as filed with the securities and exchange commission on february 5, 2024 registration no. 333- united states securities and exchange commission washington, ...
4D MOLECULAR THERAPEUTICS INC.
4D Molecular Therapeutics Announces Proposed Public Offering of Common Stock
Emeryville, calif., feb. 05, 2024 (globe newswire) -- 4d molecular therapeutics, inc. (nasdaq: fdmt), a leading clinical-stage genetic medicines company focused on unlocking the fu ...
Sei un professionista?
Abbiamo ricevuto 2.400 richieste di consulenza, pubblica il tuo profilo premium
per ricevere contatti e acquisire nuovi clienti